CIK 0002028614 · <br>Emerging growth company
Drugs Made In America Acquisition Corp.
Sign in to watch- Ticker
- DMAA
- Exchange
- Nasdaq
- Industry
- Blank Checks
- FY end
- Dec 31
- Entity type
- operating
- Phone
- 646-726-7074
- Business address
- 420 LEXINGTON AVENUE, SUITE 1402, NEW YORK, NY, 10170
Securities
- DMAA Ordinary Shares Nasdaq
- DMAAR Rights Nasdaq
- DMAAU Units Nasdaq
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-18 | Drugs Made In America Acquisition LLC 10% owner | Purchase | +30,000 | 4,188,780 | ||
| 2025-02-18 | Drugs Made In America Acquisition LLC 10% owner | Purchase · Rights to receive ordinary shares | +30,000 | 430,000 | ||
| 2025-02-18 | Stockwell Lynn CEO and Exe. Chair of Board | Purchase | +30,000 | 4,188,780 | ||
| 2025-02-18 | Stockwell Lynn CEO and Exe. Chair of Board | Purchase · Rights to receive ordinary shares | +30,000 | 430,000 | ||
| 2025-01-29 | Drugs Made In America Acquisition LLC 10% owner | Purchase | +400,000 | 10,257,143 | ||
| 2025-01-29 | Drugs Made In America Acquisition LLC 10% owner | Other disposition | −400,000 | 9,857,143 | ||
| 2025-01-29 | Drugs Made In America Acquisition LLC 10% owner | Sale | −5,698,363 | 4,158,780 | ||
| 2025-01-29 | Drugs Made In America Acquisition LLC 10% owner | Purchase · Rights to receive ordinary shares | +400,000 | 400,000 | ||
| 2025-01-29 | Stockwell Lynn CEO and Executive COB | Purchase | +400,000 | 10,257.14 | ||
| 2025-01-29 | Stockwell Lynn CEO and Executive COB | Other disposition | −400,000 | 9,857,143 | ||
| 2025-01-29 | Stockwell Lynn CEO and Executive COB | Sale | −5,698,363 | 4,158,780 | ||
| 2025-01-29 | Stockwell Lynn CEO and Executive COB | Purchase · Rights to receive ordinary shares | +400,000 | 400,000 | ||
| 2025-01-29 | Shulgan Myron W. Director | Other acquisition | +100,000 | 100,000 | ||
| 2025-01-29 | Prasad Sridhar G. Director | Other acquisition | +100,000 | 100,000 | ||
| 2025-01-29 | Do Catherine Director | Other acquisition | +100,000 | 100,000 | ||
| 2025-01-29 | Worman Glenn C. CFO | Other acquisition | +100,000 | 100,000 |
Page 1 of 1 · 16 trades